Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Eyes Triple Glory After Hat Trick of CF Approvals

Executive Summary

Symdeko, which will have a wholesale price of $292,000 per year, has got the green light in the US, adding to Vertex' already-approved cystic fibrosis treatments Kalydeco and Orkambi. Now, focus will shift onto its role in potential triple combinations for the disease.


Related Content

2018 Saw Record Launches, But No Big Splash
Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say
Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results
Vertex Secures Hat Trick Of Europe CF Approvals With Nod For Symkevi
Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy
AbbVie To Take Flight From Galapagos As PELICAN Flounders?
Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals
Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal
Galapagos Glides Towards Triple Combo Studies In Cystic Fibrosis
Vertex Strikes Novel Reimbursement Deal For Cystic Fibrosis Drugs in Ireland


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts